The Altasciences Group is proud to announce the addition of Vince and Associates Clinical Research to its team providing comprehensive Phase I/IIa clinical drug development capabilities.
Based in Overland Park, Kansas since 2001, Vince and Associates has become an established industry leader in the successful recruitment and retention of special populations in complex early development clinical trials. The Vince and Associates approach, where study teams are led by highly experienced Principal Investigators intricately involved in all aspects of the clinical trial process, has generated significant industry demand for their services from both large pharmaceutical and biotechnology clients.
“We continue to benefit from the industry shift towards these types of complex studies and joining the Altasciences team will significantly enhance our capabilities while allowing us to continue the responsive delivery of quality research data to our global biopharmaceutical clients,” said Dr. Brad Vince, Founder, President and Medical Director of Vince and Associates. Dr. Vince will continue to act as the CEO and Medical Director.
Altasciences, owned by Kilmer Capital Partners, also owns Algorithme Pharma, a Montreal based full service early stage clinical CRO. Both Vince and Associates Clinical Research and Algorithme Pharma operate with a common mission, to provide the best quality early stage clinical development services to an international customer base of pharmaceutical, biotechnology and generic companies with a focus on customer service.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Full Phase IIIb BATURA Trial Results Show Airsupra Cuts Severe Exacerbations by 47% in Mild Asthma
May 20th 2025Results from the pivotal BATURA trial show that Airsupra (albuterol/budesonide) significantly outperformed albuterol monotherapy in reducing severe asthma exacerbations and systemic corticosteroid exposure, reinforcing its role as a next-generation, anti-inflammatory rescue therapy for mild asthma patients.